The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study “pilot study”-Reference-Cited by-同舟云学术

The effect of hydroxychloroquine on pregnancy outcomes in patients with unexplained recurrent pregnancy loss: a placebo-controlled study “pilot study”

Published:2022-11-17 Issue:8 Volume:42 Page:3471-3476
ISSN:0144-3615
Container-title:Journal of Obstetrics and Gynaecology
language:en
Short-container-title:Journal of Obstetrics and Gynaecology

Author:

Moini Ashraf¹²³,Sepidarkish Mahdi⁴^ORCID,Dehpour Ahmad Reza⁵⁶^ORCID,Rabiei Maryam¹,Abiri Ameneh¹,Pirjani Reihaneh¹

Affiliation:

1. Obstetrics and Gynecology Department, Tehran University of Medical Sciences, Tehran, Iran

2. Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran

3. Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine

4. Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran

5. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

6. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology

Link

https://www.tandfonline.com/doi/pdf/10.1080/01443615.2022.2141615

Reference28 articles.

1. Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: Non randomized, open-label clinical trial

2. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study

3. Hydroxychloroquine in lupus pregnancy

4. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydroxychloroquine in recurrent pregnancy loss: data from a French prospective multicenter registry;Human Reproduction;2024-06-28

2. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database;Brazilian Journal of Medical and Biological Research;2024